Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease

BACKGROUND: Cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) in patients without cardiovascular or renal disease, a majority of newly diagnosed patients with type 2 diabetes often excluded from clinical trials on this association, is poorly understood. Thus, we investigate the ri...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Baksh, Sheriza N., Segal, Jodi B., McAdams-DeMarco, Mara, Kalyani, Rita R., Alexander, G. Caleb, Ehrhardt, Stephan
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2020
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7561135/
https://ncbi.nlm.nih.gov/pubmed/33057387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0240141
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items